11. Meta-analysis of effectiveness outcomes with exclusion of studies, which contribute to heterogeneity (fixed-effect model) Survival, percentage (95% confidence interval) Indication N studies On N studies At N studies 30-day (n pts) support (n pts) discharge (n pts) VAD support in pre-cardiotomy 88% 72% 4 (40) - - 5 (60) cardiogenic indication (76-96%) (60-83%) VAD support in post-LVAD placement 54% 73% - - 3 (48) 2 (36) right ventricular failure indication (40-68%) (57-86%) Pts patients; VAD, ventricular assist device. –
11. Meta-analysis of effectiveness outcomes with exclusion of studies, which contribute to heterogeneity (fixed-effect model) Indication Survival, percentage (95% confidence interval) N studies (n pts) On support N studies (n pts) At discharge N studies (n pts) 30-day VAD support in pre-cardiotomy cardiogenic indication 4 (40) 88% (76-96%) - - 5 (60) 72% (60-83%) VAD support in post-LVAD placement right ventricular failure indication - - 3 (48) 54% (40-68%) 2 (36) 73% (57-86%) Pts – patients; VAD, ventricular assist device.
ASAIO_2014_07_02_BORISENKO_ASAIO-D-14011R1_SDC1.docx